New research group launched by SMART, Critical Analytics for Manufacturing Personalized-Medicine (CAMP) as part of Singapore’s National Cell Manufacturing Initiative.
Cell therapies currently face significant challenges in its widespread adoption including safety, potency, efficacy, and costs. To overcome these challenges, the Singapore-MIT Alliance for Research and Technology (SMART), together with A*STAR Institutes and supported by the National Research Foundation (NRF), has launched a new national initiative in Singapore that deploys MIT’s globally renowned applied innovation methodology combined with Singapore’s dynamic and growing biopharmaceutical manufacturing industry.
As part of the national initiative in cell manufacturing, CAMP is a new interdisciplinary research group within SMART that will focus on ways to produce living cells as medicine delivered to humans, leading to improved health outcomes. The National Research Foundation will support this multi-million, multi-year project that will bring together 35 MIT and Singapore investigators. They will be recruited from researchers working in SMART and Singapore institutes including A*STAR, KK Women’s and Children’s Hospital, the National University Hospital and local universities. Investigators from MIT in Cambridge, Massachusetts will also be recruited to support the programme.
This initiative looks to apply the problem-solving research methodology from SMART and Singapore’s well-established biopharmaceutical manufacturing ecosystem to achieve market-ready breakthroughs.
SMART CAMP will be helmed by Professor Krystyn Van Vliet of MIT and Professor Hanry Yu of NUS and A*STAR. [APBN]